How Does Tirzepatide Work? The Dual Mechanism

How does tirzepatide work? It is one peptide engineered to activate two incretin receptors: GIP and GLP-1. That dual signal helps pancreatic beta cells release insulin when glucose is elevated, can reduce glucagon concentrations, slows stomach emptying most noticeably early in treatment, and changes appetite signalling so less food may feel sufficient. Semaglutide activates only the GLP-1 receptor. Tirzepatide therefore overlaps with semaglutide but adds GIP-receptor activity; researchers are still working out exactly how much each receptor contributes to each clinical effect.

How does tirzepatide work at two receptors?

GIP and GLP-1 are incretin hormones. The intestine releases them after nutrients arrive, and both help connect a meal to the pancreatic response that follows. Tirzepatide is a long-acting molecule built from a GIP-based sequence that can bind and activate both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Its roughly five-day half-life supports sustained exposure between weekly injections, according to the February 2026 FDA prescribing information.

The original discovery work did more than attach a dual-agonist label. In cell and animal experiments, tirzepatide activated both human receptors and increased glucose-stimulated insulin secretion (Coskun et al., Molecular Metabolism 2018). Later receptor studies found an uneven profile: tirzepatide behaves much like native GIP at GIPR, while at GLP-1R it favors cyclic AMP signalling over beta-arrestin recruitment and causes less receptor internalization than native GLP-1 (Willard et al., JCI Insight 2020). That is useful molecular detail, but it does not tell us that one pathway alone explains an individual person's response.

From receptor signal to blood glucose

When glucose is elevated, GIPR and GLP-1R signalling in pancreatic beta cells raises cyclic AMP and amplifies insulin release. The words glucose-dependent matter: the signal is tied to the presence of glucose, rather than forcing the same insulin output at every glucose level. Tirzepatide also reduces fasting and post-meal glucagon concentrations. Because glucagon normally tells the liver to release glucose, less glucagon can reduce another source of glucose entering the bloodstream.

A 28-week randomized phase 1 study put that physiology under direct measurement. Among 117 adults with type 2 diabetes, tirzepatide improved a clamp-based disposition index that combines insulin secretion and insulin sensitivity by 1.9 units from baseline, versus essentially no change with placebo. The improvement was also greater than with semaglutide, with an estimated between-treatment difference of 0.84 units (Heise et al., The Lancet Diabetes & Endocrinology 2022). This was a small mechanistic study using specific doses, not a prediction of what any one patient will experience.

Gastric emptying slows, then the effect fades

Tirzepatide delays gastric emptying, meaning food leaves the stomach more slowly. Nutrients then reach the small intestine and bloodstream at a slower rate, which can soften the rise in glucose after a meal. The same process can contribute to earlier fullness, nausea or a sense that a meal is sitting longer. It can also affect how quickly some oral medicines are absorbed.

The effect is not fixed across treatment. A pharmacology study using acetaminophen absorption as an indirect marker found that a first tirzepatide dose delayed gastric emptying. The effect diminished after repeated exposure, although some delay remained during dose escalation in participants with type 2 diabetes (Urva et al., Diabetes, Obesity and Metabolism 2020). Slower emptying is therefore part of the mechanism, especially early on, but it is not a complete explanation for longer-term appetite or weight changes.

Satiety signalling changes the eating decision

GLP-1 and GIP receptors also participate in gut-to-brain and brain circuits involved in appetite. In practical terms, tirzepatide has been associated with less hunger, fewer food cravings, less tendency to overeat and reduced food intake under controlled test conditions. “Satiety signalling” is more accurate than saying the medicine simply keeps food in the stomach.

In a six-week randomized phase 1 trial of 114 adults with overweight or obesity and without diabetes, participants assigned tirzepatide ate an estimated 524.6 fewer calories than placebo during a test lunch at week 3. They also reported lower overall appetite, hunger and cravings (Martin et al., Nature Medicine 2025). That number describes one meal in one short study. It is not a daily calorie forecast.

Tirzepatide versus semaglutide: two receptors versus one

The cleanest difference is the target, not a slogan about which medicine is stronger. Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide activates GLP-1R and GIPR in the same molecule.

Adding GIPR activity does not mean every effect is doubled. In a separate 28-week analysis, both medicines reduced appetite and test-meal energy intake, with no significant difference between them on those measures (Heise et al., Diabetes Care 2023). Their different outcomes cannot be assigned to hunger alone. Insulin sensitivity, beta-cell function, dose, exposure, tolerability and biology outside the measured test meal may all matter. The broader tirzepatide versus semaglutide comparison covers clinical differences beyond receptor pharmacology.

What the mechanism cannot decide

A mechanism explains what a molecule is capable of doing. It does not select the right medication, dose or titration pace for a particular person. Gastric effects help explain why nausea, constipation, diarrhea and vomiting can occur; tirzepatide side effects covers those risks in context. Dose escalation changes exposure and tolerability, but the prescriber sets the actual dose; the tirzepatide dosage schedule explains how that decision is made.

The studies above evaluated investigational or branded tirzepatide, not Promise's formulation. Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA's compounding guidance explains that compounded drugs do not undergo its premarket review for safety, effectiveness or quality. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

At Promise, a licensed U.S. provider reviews every request and prescribes or declines based on medical eligibility. Not everyone qualifies. If a prescription is written, a licensed U.S. compounding pharmacy prepares and dispenses the medication.

The useful summary is specific: tirzepatide engages two incretin receptors, increases glucose-responsive insulin secretion, reduces glucagon, transiently slows gastric emptying and changes appetite signalling. Semaglutide shares the GLP-1 portion of that story but not the GIP-receptor component. The dual design is established; the exact contribution of each signal in an individual remains a clinical and scientific question.